Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–22 of 22 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Pyridoxal 5'-Phosphate Clear all

Conditions: Advanced Metastatic (Stage IV) Colorectal Cancer
Interventions: PledOx (2 µmol/kg), PledOx (5 µmol/kg), PledOx (10 µmol/kg), Placebo (0,9% NaCl); Drug
Lead sponsor: Egetis Therapeutics AB (publ); Industry
Eligibility: 18 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 6
States / cities: La Jolla, California • Bethesda, Maryland • Chattanooga, Tennessee + 3 more

Conditions: Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency
Interventions: Pyridoxal 5'-Phosphate; Drug
Lead sponsor: Medicure; Industry
Eligibility: 2 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: Palo Alto, California • Aurora, Colorado • Boston, Massachusetts

Conditions: Gyrate Atrophy
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1978 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chemotherapy Induced Peripheral Neuropathy (CIPN)
Interventions: Calmangafodipir, Placebo; Drug
Lead sponsor: Egetis Therapeutics AB (publ); Industry
Eligibility: 20 Years to 55 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Cypress, California

Conditions: Sleep Quality, Sleep Health
Interventions: Sleep Supplement, Placebo; Dietary Supplement
Lead sponsor: 4Life Research, LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Sandy City, Utah

Conditions: COVID-19, Acute Respiratory Distress Syndrome, SARS-CoV-2, Hypoxemia
Interventions: Rejuveinix (RJX) Active Comparator, Placebo Comparator; Drug
Lead sponsor: Reven Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: Houston, Texas • New Braunfels, Texas

Conditions: Optic Disc Edema, Endothelial Dysfunction
Interventions: Vitamin B-Complex Supplement; Drug
Lead sponsor: National Aeronautics and Space Administration (NASA); Federal
Eligibility: 20 Years to 100 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2035
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetic Peripheral Neuropathy
Interventions: Metanx® (Oral L-methylfolate, Methylcobalamin and Pyridoxal 5'-phosphate); Other
Lead sponsor: Carolina Musculoskeletal Institute; Other
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2006
U.S. locations: 1
States / cities: Aiken, South Carolina

Conditions: Coronary Artery Bypass Graft Surgery, Myocardial Ischemia, Reperfusion Injury
Interventions: (MC-1) Pyridoxal 5'-phosphate; Drug
Lead sponsor: Medicure; Industry
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Colorectal Cancer, Chemotherapy-induced Peripheral Neuropathy
Interventions: Calmangafodipir (2 µmol/kg), Calmangafodipir (5 µmol/kg), Placebo; Drug
Lead sponsor: Egetis Therapeutics AB (publ); Industry
Eligibility: 18 Years and older
Enrollment: 291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 11
States / cities: Fresno, California • Orange City, Florida • Wichita, Kansas + 8 more

Conditions: Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency
Interventions: Pyridoxal Phosphate; Drug
Lead sponsor: Medicure; Industry
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 6
States / cities: Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 3 more

Conditions: Type 2 Diabetic Peripheral Neuropathy (DPN)
Interventions: Metanx (a medical food), Metanx placebo; Other
Lead sponsor: Pamlab, Inc.; Industry
Eligibility: 25 Years to 80 Years
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 6
States / cities: Birmingham, Alabama • New Orleans, Louisiana • Omaha, Nebraska + 3 more

Conditions: Receptor Blockade
Interventions: Adenosine Triphosphate, Acetylcholine, Sodium Nitroprusside, Adenosine Diphosphate, Adenosine Monophosphate, Uridine Triphosphate, Adenosine, Vitamin B 6, Pyridoxal 5'-Phosphate; Drug
Lead sponsor: Colorado State University; Other
Eligibility: 18 Years to 30 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Fort Collins, Colorado

Conditions: Hemorrhagic Shock
Interventions: Poly SFH-P Injection; Drug
Lead sponsor: Northfield Laboratories; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 32
States / cities: San Diego, California • Denver, Colorado • Newark, Delaware + 25 more

Conditions: Chronic Pain
Interventions: Inflammation Support Formula, Nerve Health Formula, Redox Support Formula; Dietary Supplement
Lead sponsor: Ethos Research & Development; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Newport, Kentucky

Conditions: Diabetic Peripheral Neuropathy (DPN)
Interventions: Metanx® (a medical food), Not treated with Metanx®; Other
Lead sponsor: Pamlab, L.L.C.; Industry
Eligibility: 25 Years to 80 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: Safety, Tolerance
Interventions: Crystal Light (once serving), Liquid IV with amino acids (one serving), Liquid IV with amino acids (two servings), Liquid IV with amino acids (three servings); Dietary Supplement
Lead sponsor: University of Memphis; Other
Eligibility: 18 Years to 50 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Coronary Artery Bypass Graft Surgery, Myocardial Ischemia, Reperfusion Injury, Myocardial Revascularization
Interventions: (MC-1) Pyridoxal-5'-phosphate; Drug
Lead sponsor: Medicure; Industry
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Diabetic Peripheral Neuropathy
Interventions: Metanx® (a medical food); Other
Lead sponsor: Pamlab, L.L.C.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Montgomery, Alabama

Conditions: Epilepsy
Interventions: Mangafodipir, Gadolinium; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sleep
Interventions: Placebo Capsule, POWEROFF Capsule; Dietary Supplement
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Multiple Sclerosis
Interventions: Mangafodipir (Teslascan); Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

A Trial of PledOx + FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Metastatic Colorectal Cancer

Continuation Study With Oral MC-1 for Treatment of Patients With PNPO-Deficiency

Gyrate Atrophy of the Choroid and Retina

SUNCIST: A Study of Calmangafodipir in Healthy Japanese and Caucasian Subjects

Clinical Study to Assess a Dietary Supplement on Sleep Health and Quality

Tolerability and Efficacy of RJX in Patients With COVID-19

B-Complex: A Nutraceutical SANS Countermeasure

Restoration of Cutaneous Sensorum in Patients With Diabetic Peripheral Neuropathy (DPN) Via Metanx®

A Safety and Efficacy Study to Confirm the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk CABG

Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M)

Oral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency

Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN)

Pyridoxine, P2 Receptor Antagonism, and ATP-mediated Vasodilation in Young Adults

Safety and Efficacy of PolyHeme(R) in Hemorrhagic Shock Following Traumatic Injuries Beginning in the Pre-Hospital Setting

Pilot Study: Impact of Biomarker-Guided Dietary Supplementation on Quality-of-Life Measures in Subjects With Chronic Pain

Administrative Claims Analysis of Metanx® in Diabetic Peripheral Neuropathy

Safety and Tolerability of a Novel Amino-acid Based Hydration Drink in Healthy Volunteers

MEND-CABG (MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery)

Metanx® P.L.U.S. Program (Progress Through Learning, Understanding & Support)

Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy

The Poweroff Sleep Study

Manganese-Enhanced Magnetic Resonance Imaging in Healthy Volunteers and People With Multiple Sclerosis